Equity Brief · Healthcare2026-10-27
ORIOLA.HE·Healthcare

Next reporting 29 Oct 2026Tomorrow

Oriola Oyj

I · AI Analysis

The brief

Oriola operates as a pharmaceutical wholesaler and logistics provider, distributing prescription medicines, over-the-counter products, vitamins, vaccines, and health-related items to pharmacies, hospitals, veterinarians, and retailers across Nordic markets. The company also provides specialized services including dose dispensing for patients, clinical trial logistics, regulatory affairs support, and patient support programs for pharmaceutical manufacturers.

Oriola is a Finnish pharmaceutical wholesale and logistics company that distributes medicines, vitamins, and health products to pharmacies, hospitals, and healthcare providers across Sweden, Finland, and other markets [Yahoo Finance]. The company has been in operation since 1907 and employs 796 people [Yahoo Finance]. Through the trailing twelve months ended 30 June 2026, Oriola generated EUR 1.9B in revenue but posted a net loss, reflecting one-time charges that depressed reported earnings [Yahoo Finance].

Oriola's financials show thin operating margins and a trailing net loss driven by one-time charges, though operating performance improved in the latest quarter.

The brief AI analysisConfidence 5/10

Sentinellis health

Significant risks

3.8/10

7.5+ strong · 4.5–7.5 moderate · under 4.5 weak

Profitability

14% of score0.0/10
Net margin-1.0%· need ≥ 6.9%, the lower third of Healthcare in our libraryGross margin+8.8%· need ≥ 57.4%, the lower third of Healthcare in our library

Returns on capital

14% of score0.0/10
ROIC+5.5%· need > 10%Return on equity-22.1%· need > 12%

Growth & momentum

19% of score5.0/10
Revenue growth+1.8%· need ≥ 2.9%, the lower third of Healthcare in our libraryOperating margin trend+6.7pp YoY

Balance sheet

29% of score5.0/10
Current ratio0.8x· need > 1.2xNet debt / EBITDA-3.2xInterest coverage1.2x· need > 6.0xDebt / equity0.88

Cash generation

14% of score3.3/10
Free cash flowEUR -2.9M· need positiveCash vs reported profitEUR 6.8M vs EUR -19.5M

Value creation

10% of score10.0/10
ROIC vs cost of capital+0.3pp

Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.

Market capitalisation

EUR 138.7M

Revenue (TTM)

EUR 1.9B

Explainers

How we read these numbers

Plain-English guides · no account needed

Premium · Free with any account

Oriola operates in a low-margin wholesale distribution business — its trailing-twelve-month operating margin is only 0.2%, leaving little cushion against cost inflation, pricing pressure from customers, or disruptions in pharmaceutical supply chains [Yahoo Finance].

1 of 5 risks in this report

Risks

5

Opportunities

5

Red flags

1

Leadership

10

10 more findings in the full report — free with any account.

Unlock the full Oriola Oyj analysis

Create a free account to access the complete AI-generated report with inline citations.

  • 5 risks, 5 opportunities and 1 red flag — each with its source
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Unlock all 11 findings3 free reports · No credit card

III · Related

You might also read

Same sector · Healthcare — or comparable health

Want this for your watchlist?

Read three companies free. No card.

Get 3 free reports

Produced 27 Oct 2026, 11:04 UTC

Figures come from company filings and market data. The Sentinellis health score and the wording attached to it are our interpretation of those figures, not numbers the company reported.

Not investment advice and not a recommendation to buy or sell. Sentinellis holds no positions in the companies it covers, takes no payment from issuers, and has no broker referral arrangements.

How every figure and score is calculated